Lannett provides update on biosimilar insulin glargine trials

Lannett provided an update on its pivotal clinical trials of biosimilar insulin glargine.  Lannett announced that half of the subjects have received the first two doses in healthy volunteer pharmacokinetics (PK) and pharmacodynamics (PD) study.  No serious adverse events have been reported, with the study due to finish at the end of 2022.  Lannett also announced that it plans to submit its BLA for the project in early 2023, with a potential launch in the first half of 2024.